Abstract
Objective
To investigate the factors favoring a positive prognosis for advanced primary peritoneal carcinoma (PPC).
Methods
Twenty-four cases meeting the criteria for PPC were analyzed retrospectively for the clinicopathologic profiles. Immunohistochemistry was used to determine the expressions of p53, Top2α, Ki-67 and Her-2/neu. Then all these clinicopathological factors and molecular markers were correlated with the prognosis.
Results
There were 15 cases of primary peritoneal serous papillary carcinoma (PPSPC), 6 cases of mixed epithelial carcinoma (MEC) and 3 cases of malignant mixed Mullerian tumor (MMMT). All patients underwent cytoreductive surgery with optimal debulking achieved in 3 cases. Among those receiving first-line chemotherapy, 13 patients received the TP regimen (paclitaxel-cisplatin or carboplatin) and 7 patients received the PAC regimen (cisplatin-doxorubicin-cyclophosphamide). The median overall survival of all patients was 42 months, while the breakdown for survival time for patients with PPSPC, MMT and MEC was 44, 13 and 19 months, respectively. The expressions of p53, Top2α and Ki-67 were all demonstrated in 11 cases respectively. None showed the expression of Her-2/neu. There were significant differences in the median survival between patients with PPSPC and those with MMMT (44 months vs 13 months, P<0.05), also between patients receiving TP combination and those receiving the PAC regimen (75 months vs 28 months, P<0.05). Another significant difference in the median progression-free survival (PFS) was identified between patients with positive p53 immunostaining and those with negative p53 immunostaining (15 months vs 47 months, P<0.05), whereas age, menopausal status, residual tumor size and the other molecular factors did not significantly impact survival.
Conclusion
Patients with PPC should be treated with a comprehensive management plan including appropriate cytoreductive surgery and responsive chemotherapy. Overestimating an optimal debulking surgery may not benefit survival. The pathologic subtype, chemotherapy regimen and p53 overexpression were significant prognostic factors.
Similar content being viewed by others
References
Altaras, M.M., Aviram, R., Cohen, I., Cordoba, M., Weiss, E., Beyth, Y., 1990. Primary peritoneal papillary serous adenocarcinoma: clinical and management aspects. Gynecol. Oncol., 40(3):230–236. [doi:10.1016/0090-8258(90)90283-Q]
Ben-Baruch, G., Sivan, E., Moran, O., Rizel, S., Menczer, J., Seidman, D.S., 1996. Primary peritoneal serous papillary carcinoma: a study of 25 cases and comparison with stage III–IV ovarian papillary serous carcinoma. Gynecol. Oncol., 60(3):393–396. [doi:10.1006/gyno.1996.0060]
Bloss, J.D., Liao, S.Y., Buller, R.E., Manetta, A., Berman, M.L., McMeekin, S., Bloss, L.P., DiSaia, P.J., 1993. Extraovarian peritoneal serous papillary carcinoma: a case-control retrospective comparison to papillary adenocarcinoma of the ovary. Gynecol. Oncol., 50(3):347–351. [doi:10.1006/gyno.1993.1223]
Bloss, J.D., Brady, M.F., Liao, S.Y., Rocereto, T., Partridge, E.E., Clarke-Pearson, D.L., Gynecologic Oncology Group Study, 2003. Extraovarian peritoneal serous papillary carcinoma: a phase II trial of cisplatin and cyclophosphamide with comparison to a cohort with paillary serous ovarian carcinoma. Gynecol. Oncol., 89(1):148–154. [doi:10.1016/S0090-8258(03)00068-4]
Chu, C.S., Menzin, A.W., Leonard, D.G., Rubin, S.C., Wheeler, J.E., 1999. Primary peritoneal carcinoma: a review of the literature. Obstet. Gynecol. Surv., 54(5):323–335. [doi:10.1097/00006254-199905000-00023]
Dubernard, G., Morice, P., Rev, A., Camatte, S., Fourchotte, V., Thoury, A., Pomel, C., Pautier, P., Lhommé, C., Duvillard, P., 2004. Prognosis of stage III or IV primary peritoneal serous papillary carcinoma. Eur. J. Surg. Oncol., 30(9):976–981. [doi:10.1016/j.ejso.2004.08.005]
Eltabbakh, G.H., Werness, B.A., Piver, S., Blumenson, L.E., 1998a. Prognostic factors in extraovarian primary peritoneal carcinoma. Gynecol. Oncol., 71(2):230–239. [doi:10.1006/gyno.1998.5090]
Eltabbakh, G.H., Piver, M.S., Natarajan, N., Mettlin, C.J., 1998b. Epidemiologic differences between women with extraovarian primary peritoneal carcinoma and women with epithelial ovarian cancer. Obstet. Gynecol., 91(2):254–259. [doi:10.1016/S0029-7844(97)00650-9]
Fromm, G.L., Gershenson, D.M., Silva, E.G., 1990. Papillary serous carcinoma of the peritoneum. Obstet. Gynecol., 75(1):89–95.
Garamvoelgyi, E., Guillou, L., Gebhard, S., Salmeron, M., Seematter, R.J., Hadji, M.H., 1994. Primary malignant mixed mullerian tumor (metaplastic carcinoma) of the female peritoneum: a clinical, pathologic and immunohistochemical study of three cases and a review of the literature. Cancer, 74(3):854–863. [doi:10.1002/1097-0142(19940801)74:3〈854::AID-CNCR2820740311〉3.0.CO;2-R]
Gotlieb, W.H., Goldberg, I., Weisz, B., Davidson, B., Novikov, I., Kopolovic, J., Ben-Baruch, G., 2001. Topoisomerase II immunostaining as a prognostic marker for survival in ovarian cancer. Gynecol. Oncol., 82(1):99–104. [doi:10.1006/gyno.2001.6208]
Halperin, R., Zehavi, S., Hadas, E., Habler, L., Bukovsky, I., Schneider, D., 2001. Immunohistochemical comparison of primary peritoneal and primary ovarian serous papillary carcinoma. Int. J. Gynecol. Pathol., 209(4):341–345. [doi:10.1097/00004347-200110000-00005]
Killackey, M.A., Davis, A.R., 1993. Papillary serous carcinoma of the peritoneal surface: matched-case comparison with papillary serous ovarian carcinoma. Gynecol. Oncol., 51(2):171–174. [doi:10.1006/gyno.1993.1267]
Kowalski, L.D., Kanbour, A.I., Price, F.V., Finkelstein, S.D., Christopherson, W.A., Seski, J.C., Naus, G.J., Burnham, J.A., Kanbour-Shakir, A., Edwards, R.P., 1997. A casematched molecular comparison of extraovarian versus primary ovarian adenocarcinoma. Cancer, 79(8):1587–1594. [doi:10.1002/(SICI)1097-0142(19970415)79:8〈1587::AID-CNCR22〉3.0.CO;2-T]
Look, M., Chang, D., Sugarbaker, P.H., 2004. Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum. Int. J. Gynecol. Cancer, 14(1):35–41. [doi:10.1111/j.1048-891x.2004.14008.x]
Menzin, A.W., Aikins, J.K., Wheeler, J.E., Rubin, S.C., 1996. Surgically documented responses to paclitaxel and cisplatin patients with primary peritoneal carcinoma. Gynecol. Oncol., 62(1):55–58. [doi:10.1006/gyno.1996.0189]
Mills, S.E., Andersen, W.A., Fechner, R.E., Austin, M.B., 1988. Serous surface papillary carcinoma: a clinicopathologic study of 10 cases and comparison with stage III–IV ovarian serous carcinoma. Am. J. Surg. Pathol., 12(11):827–834.
Muto, M.G., Welch, W.R., Mok, S.C., Bandera, C.A., Fishbauqh, P.M., Tsao, S.W., Lau, C.C., Goodman, H.M., Knapp, R.C., Berkowitz, R.S., 1995. Evidence for a multifocal origin of papillary serous carcinoma of the peritoneum. Cancer Res., 55(3):490–492.
Piver, M.S., Eltabbakh, G.H., Hempling, R.E., Recio, F.O., Blumenson, L.E., 1997. Two sequential studies for primary peritoneal carcinoma: induction with weekly cisplatin followed by either cisplatin-doxorubicin-cyclophosphamide or paclitaxel-cisplatin. Gynecol. Oncol., 67(2):141–146. [doi:10.1006/gyno.1997.4843]
Shen, D.H., Khoo, U.S., Xue, W.C., Ngan, H.Y., Wang, J.L., Liu, V.W., Chan, Y.K., Cheung, A.N., 2001. Primary peritoneal malignant mixed Mullerian tumors. A clinicopathologic, immunohistochemical and genetic study. Cancer, 91(5):1052–1060. [doi:10.1002/1097-0142(20010301)91:5〈1052::AID-CNCR1097〉3.3.CO;2-1]
Swerdlow, M., 1959. Mesothelioma of the pelvic peritoneum resembling papillary cystadeno-carcinoma of the ovary. Case Report. Am. J. Obstet. Gynecol., 77(1):197–200.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zhang, C., Li, Xp., Cui, H. et al. Advanced primary peritoneal carcinoma: clinicopathological and prognostic factor analyses. J. Zhejiang Univ. Sci. B 9, 435–440 (2008). https://doi.org/10.1631/jzus.B0820051
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1631/jzus.B0820051